Travere Therapeutics submits sNDA for full approval of Filspari (sparsentan) for IgA nephropathy treatment based on Phase 3 PROTECT study.

Travere Therapeutics submits sNDA to FDA for full approval of Filspari (sparsentan) for IgA nephropathy treatment. Filspari was granted accelerated approval in Feb 2020 to reduce proteinuria in IgAN patients. Phase 3 PROTECT study demonstrated long-term kidney function preservation and significant reduction in proteinuria vs active comparator.